Get the Stockscreener App
4.005
2.96%
0.115
After Hours:
4.01
0.005
+0.12%
Molecular Partners Ag Adr stock is traded at $4.005, with a volume of 631.
It is up +2.96% in the last 24 hours and up +5.39% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
See More
Previous Close:
$3.89
Open:
$4.005
24h Volume:
631
Relative Volume:
0.10
Market Cap:
$150.23M
Revenue:
$786.00K
Net Income/Loss:
$-72.06M
P/E Ratio:
-2.0801
EPS:
-1.9254
Net Cash Flow:
$-59.83M
1W Performance:
+0.12%
1M Performance:
+5.39%
6M Performance:
+0.12%
1Y Performance:
+3.53%
1-Day Range:
$4.005
$4.005
1-Week Range:
$3.89
$4.11
52-Week Range:
$3.4101
$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
4.005 | 145.92M | 786.00K | -72.06M | -59.83M | -1.9254 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | H.C. Wainwright | Buy |
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners reports progress in MP0317 clinical trial - grafa.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com - Investing.com Nigeria
Molecular Partners advances MP0712 cancer trial - grafa.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress - Investing.com
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
A3CSB5 Forecast — Price Target — Prediction for 2027 - TradingView
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - GlobeNewswire Inc.
MOLN - Finviz
Molecular Partners reports phase 1 data for cancer drug MP0317 By Investing.com - Investing.com Australia
Molecular Partners reports phase 1 data for cancer drug MP0317 - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April - MarketBeat
Head & ShouldersStock ScreenerCharts - Finviz
Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Molecular Partners stock rating at buy - Investing.com
H.C. Wainwright reiterates Molecular Partners stock rating at buy By Investing.com - Investing.com South Africa
Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%Still a Buy? - MarketBeat
Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9% - MarketBeat
HC Wainwright Brokers Increase Earnings Estimates for MOLN - Defense World
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential By Investing.com - Investing.com South Africa
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential - Investing.com
Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Molecular Partners (NASDAQ: MOLN) outlines DARPin pipeline and cash into 2028 - Stock Titan
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production? - TradingView
Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday - Defense World
Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5%Should You Sell? - MarketBeat
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready - Yahoo Finance
Research Analysts Offer Predictions for MOLN FY2025 Earnings - Defense World
Brokers Offer Predictions for MOLN FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings? - MarketBeat
Molecular Partners stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Molecular Partners stock initiated with Buy rating at H.C. Wainwright - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1% – Here’s What Happened - Defense World
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners to cut workforce by a quarter - Reuters
Citius Oncology (CTOR) Short Interest & Short Float | Updated Apr 2026 $CTOR - MarketBeat
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com Nigeria
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com
Molecular Partners reports 2024 annual results - Investing.com
Molecular Partners (MOLN) Stock Forecast and Price Target 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (MIRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Stock Market News Today - Stock Titan
MAIA Biotechnology (MAIA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):